Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 297 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Boy Asks Mom Fighting Cancer To Take Off Her Turban So... May 4, 2020 For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... August 29, 2022 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... January 16, 2023 How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Load more HOT NEWS Immune Pathways Help Identify Patients with Cancer and HIV Most Likely... Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane... TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced...
